Key result
Systematic review evaluates statin-associated myopathy and hepatotoxicity in cancer patients without reported quantitative outcomes.
Why the study?
The risk of clinically relevant myopathy and hepatotoxicity in patients with cancer receiving statin therapy compared to placebo or no treatment was unclear.
Systematic Review
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Cancer history, treatment-related toxicity and metabolic derangements, ASCVD risk factors, competing mortality, prognosis, and drug interactions must be incorporated into lipid-management decisions rather than treated as secondary considerations.”
Demands individualized statin risk-benefit assessment incorporating cancer-specific factors; leaves open optimal lipid strategies pending dedicated oncology trials.
RCTs of patients with cancer who were assigned to statin therapy versus placebo or no treatment to assess the risk of clinically relevant myopathy and hepatotoxicity. We searched MEDLINE with the PubMed interface for RCTs that randomized adult patients (aged ⩾ 18 years) with cancer to any statin therapy versus placebo or no treatment. A confirmatory search was performed with EMBASE along with a manual review of the reference list of relevant articles. We set no restriction on language, type or dose of statin, or type of cancer, although only studies with available full-text publication were considered for review, unless the abstract explicitly reported the safety outcomes. No restriction was set for the type or dose of the statins or the type of cancer. The main adverse hepatic outcomes were defined as a significant elevation in transaminases requiring medical attention, including stopping the drug or an unscheduled visit according to the definition in the individual studies, although any reported increase in hepatic enzymes was also noted. The main muscle-related adverse outcome was reported as, and objectively confirmed, myopathy, and elevation of creatine kinase as defined by individual studies was also explored. Myalgia and other subjective symptoms were not considered among the main outcomes since recent evidence
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Bikdeli et al. (2024) conducted a systematic review in Cancer. Statin therapy vs. Placebo or no treatment was evaluated on Clinically relevant myopathy and hepatotoxicity. The abstract outlines a systematic review of statin therapy for myopathy and hepatotoxicity in cancer patients, but provides no quantitative results.
Synapse has enriched 10 related papers. Consider them for comparative context: